JP6909155B2 - Ｃｎｓ障害を処置するための組成物および方法 - Google Patents

Ｃｎｓ障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP6909155B2
JP6909155B2 JP2017520471A JP2017520471A JP6909155B2 JP 6909155 B2 JP6909155 B2 JP 6909155B2 JP 2017520471 A JP2017520471 A JP 2017520471A JP 2017520471 A JP2017520471 A JP 2017520471A JP 6909155 B2 JP6909155 B2 JP 6909155B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
disorders
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017520471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531019A5 (enExample
JP2017531019A (ja
Inventor
ボテーラ， ガブリエル マルティネス
ボテーラ， ガブリエル マルティネス
フランセスコ ジー． サリトゥロ，
フランセスコ ジー． サリトゥロ，
アルバート ジーン ロビチャウド，
アルバート ジーン ロビチャウド，
ボイド エル． ハリソン，
ボイド エル． ハリソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics, LLC
Original Assignee
Sage Therapeutics, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55747445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6909155(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sage Therapeutics, LLC filed Critical Sage Therapeutics, LLC
Publication of JP2017531019A publication Critical patent/JP2017531019A/ja
Publication of JP2017531019A5 publication Critical patent/JP2017531019A5/ja
Application granted granted Critical
Publication of JP6909155B2 publication Critical patent/JP6909155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2017520471A 2014-10-16 2015-10-16 Ｃｎｓ障害を処置するための組成物および方法 Active JP6909155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064961P 2014-10-16 2014-10-16
US62/064,961 2014-10-16
PCT/US2015/056054 WO2016061527A1 (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020086704A Division JP7012119B2 (ja) 2014-10-16 2020-05-18 Ｃｎｓ障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017531019A JP2017531019A (ja) 2017-10-19
JP2017531019A5 JP2017531019A5 (enExample) 2018-11-29
JP6909155B2 true JP6909155B2 (ja) 2021-07-28

Family

ID=55747445

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017520471A Active JP6909155B2 (ja) 2014-10-16 2015-10-16 Ｃｎｓ障害を処置するための組成物および方法
JP2020086704A Active JP7012119B2 (ja) 2014-10-16 2020-05-18 Ｃｎｓ障害を処置するための組成物および方法
JP2021175469A Active JP7455098B2 (ja) 2014-10-16 2021-10-27 Ｃｎｓ障害を処置するための組成物および方法
JP2023032293A Active JP7692944B2 (ja) 2014-10-16 2023-03-02 Ｃｎｓ障害を処置するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020086704A Active JP7012119B2 (ja) 2014-10-16 2020-05-18 Ｃｎｓ障害を処置するための組成物および方法
JP2021175469A Active JP7455098B2 (ja) 2014-10-16 2021-10-27 Ｃｎｓ障害を処置するための組成物および方法
JP2023032293A Active JP7692944B2 (ja) 2014-10-16 2023-03-02 Ｃｎｓ障害を処置するための組成物および方法

Country Status (21)

Country Link
US (7) US10577390B2 (enExample)
EP (3) EP3206494A4 (enExample)
JP (4) JP6909155B2 (enExample)
KR (2) KR20230170816A (enExample)
CN (7) CN112961206A (enExample)
AR (1) AR102306A1 (enExample)
AU (5) AU2015331749A1 (enExample)
BR (1) BR112017007902B1 (enExample)
CA (1) CA2964766A1 (enExample)
CO (1) CO2017004649A2 (enExample)
IL (3) IL291533B2 (enExample)
JO (1) JO3724B1 (enExample)
MX (3) MX384728B (enExample)
MY (1) MY190408A (enExample)
NZ (1) NZ769008A (enExample)
PE (1) PE20170925A1 (enExample)
PH (2) PH12021550427A1 (enExample)
RU (2) RU2020131091A (enExample)
SG (3) SG10202009859YA (enExample)
TW (3) TWI869654B (enExample)
WO (1) WO2016061527A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
KR102121633B1 (ko) 2012-08-21 2020-06-10 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
EP2986623B1 (en) 2013-04-17 2018-11-07 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
HUE051403T2 (hu) 2013-04-17 2021-03-01 Sage Therapeutics Inc Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
LT3021852T (lt) 2013-07-19 2021-04-12 Sage Therapeutics, Inc. Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3206493B1 (en) 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN112961206A (zh) 2014-10-16 2021-06-15 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
NZ790225A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
IL315950A (en) 2016-08-23 2024-11-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
KR102526032B1 (ko) 2017-01-11 2023-04-25 로딘 테라퓨틱스, 인크. 히스톤 데아세틸라제의 바이시클릭 억제제
TWI620545B (zh) * 2017-01-20 2018-04-11 長青生醫科技股份有限公司 生物參數量測方法及其裝置
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
WO2019126741A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP2021506904A (ja) 2017-12-22 2021-02-22 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害の処置のための組成物および方法
BR112020015131A2 (pt) * 2018-02-11 2021-01-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Reguladores derivados de esteroide, método para preparar os mesmos, e usos dos mesmos
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
DK3864022T3 (da) * 2018-10-12 2023-12-18 Sage Therapeutics Inc Neuroaktive steroider substitueret i Position 10 med en cyklisk gruppe til anvendelse til behandlingen af CNS-lidelser
EP4606812A3 (en) * 2018-10-19 2025-10-15 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
CN109369762B (zh) * 2018-10-31 2021-06-18 湖南玉新药业有限公司 17-甲酸甾族化合物的制备方法
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
US20230322846A9 (en) 2018-12-05 2023-10-12 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2020124094A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
MX2021007142A (es) * 2018-12-17 2021-08-11 Intra Cellular Therapies Inc Compuestos organicos.
EP3898646A1 (en) * 2018-12-21 2021-10-27 Sage Therapeutics, Inc. 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
WO2020143640A1 (zh) * 2019-01-08 2020-07-16 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
AU2020231506A1 (en) * 2019-03-04 2021-09-30 Praxis Precision Medicines, Inc. Methods for the treatment of perimenopause and menopause
CN114206900A (zh) * 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
US20230303616A9 (en) * 2019-06-27 2023-09-28 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN115087450A (zh) * 2019-09-30 2022-09-20 艾琳治疗(英国)有限公司 优先增强gabaa受体亚型的组合物以及其使用方法
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220097394A (ko) * 2019-10-02 2022-07-07 프락시스 프리시젼 메디신즈, 인크. Gaba-a 수용체 양성 알로스테릭 조절제와 nmda 길항제, nmda 음성 알로스테릭 조절제, 또는 nmda 부분 작용제의 조합
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
WO2021252314A1 (en) * 2020-06-08 2021-12-16 Eliem Therapeutics, Inc. Methods of treating female health conditions related to sex hormones
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
US20230416300A1 (en) * 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
IT202000021316A1 (it) * 2020-09-09 2022-03-09 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders
WO2022072620A1 (en) * 2020-10-01 2022-04-07 Eliem Therapeutics (UK) Ltd Methods of treating fibromyalgia with neuroactive steroids
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
US20220296613A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Food-independent dosing of cv-10155 to treat gabaa disorders
US20220296614A1 (en) * 2021-03-19 2022-09-22 Eliem Therapeutics (UK) Ltd Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders
CN117715641A (zh) * 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
WO2023164385A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
EP4514357A1 (en) * 2022-04-26 2025-03-05 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
KR20250162825A (ko) 2023-03-14 2025-11-19 쿠리아 스페인, 에스.에이.유. 3알파-하이드록시-3베타-알킬 스테로이드의 제조를 위한 방법 및 중간체
CN116574150A (zh) * 2023-04-27 2023-08-11 广州楷石医药有限公司 一种二氢睾酮及其中间体的制备方法
WO2024238387A1 (en) * 2023-05-12 2024-11-21 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) * 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH06510999A (ja) 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
EP0567627A4 (en) 1991-11-14 1994-06-22 Stanley Poler Secondary eye growth impeding device and method
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DE69518509T2 (de) * 1994-02-14 2001-04-19 Euro-Celtique S.A., Luxemburg/Luxembourg Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
JP2002500616A (ja) 1994-07-21 2002-01-08 ファルマシア・アンド・アップジョン・カンパニー 神経学的に活性なアミノステロイド
WO1996016076A1 (en) 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
CZ394197A3 (cs) 1995-06-06 1998-06-17 Cocensys, Inc. Neuroaktivní steroidy androstanové a pregnanové řady
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
PT1172371E (pt) 2000-02-18 2005-10-31 Taiho Pharmaceutical Co Ltd Preparacao de derivados esteroides
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
US6844456B2 (en) 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
MXPA05010339A (es) 2003-03-24 2005-12-14 Sterix Ltd Derivados de estrogeno como inhibidores de la esteroide sulfatasa.
US7781421B2 (en) 2003-05-29 2010-08-24 Washington University Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
WO2005051972A1 (en) 2003-11-24 2005-06-09 Merck & Co., Inc. Estrogen receptor modulators
US20090118248A1 (en) 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
PL1888080T3 (pl) * 2005-06-09 2010-09-30 Euro Celtique Sa Kompozycje farmaceutyczne neuroaktywnego steroidu i jego zastosowanie
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
JP5663303B2 (ja) 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010054158A2 (en) 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
WO2012013816A1 (en) 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
AU2011343615A1 (en) 2010-12-15 2013-05-09 Harbor Biosciences, Inc. Methods and compounds for preparing 3alpha-oxygen substituted steroids
CZ303443B6 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
US9457033B2 (en) * 2011-02-15 2016-10-04 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9851309B2 (en) 2011-03-23 2017-12-26 Satoshi Watabe Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
AU2012323888A1 (en) 2011-10-14 2014-05-29 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
HRP20192348T1 (hr) 2012-01-23 2020-03-20 Sage Therapeutics, Inc. Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil eter beta-ciklodekstrina
WO2013188792A2 (en) 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3336097B1 (en) 2012-06-19 2020-08-19 Intercept Pharmaceuticals, Inc. Preparation of the non-crystalline form of obeticholic acid
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
KR102121633B1 (ko) 2012-08-21 2020-06-10 세이지 테라퓨틱스, 인크. 간질 또는 간질지속 상태를 치료하는 방법
US9765110B2 (en) 2012-10-08 2017-09-19 Washington University Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
HRP20181048T1 (hr) 2012-12-18 2018-08-24 Washington University Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
EP2986623B1 (en) 2013-04-17 2018-11-07 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
HUE051403T2 (hu) 2013-04-17 2021-03-01 Sage Therapeutics Inc Neuroaktív 19-nor-szteroidok kezelési eljárásokhoz
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
LT3021852T (lt) 2013-07-19 2021-04-12 Sage Therapeutics, Inc. Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
TWI839649B (zh) 2014-05-29 2024-04-21 美商賽吉醫療公司 神經活性類固醇，其組合物及其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
EP3206493B1 (en) 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN112961206A (zh) * 2014-10-16 2021-06-15 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
WO2017044659A1 (en) 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
EP3362042A1 (en) 2015-10-16 2018-08-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
MA43284A (fr) 2015-11-20 2018-09-26 Sage Therapeutics Inc Composés et leurs méthodes d'utilisation
CA3017172C (en) 2016-03-08 2023-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
NZ790225A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
IL315950A (en) 2016-08-23 2024-11-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CN111065394B (zh) 2017-08-31 2023-03-31 武田药品工业株式会社 中枢神经系统病症的治疗
SG11202002085YA (en) 2017-09-07 2020-04-29 Sage Therapeutics Inc Neuroactive steroids and their methods of use
EP3706755A4 (en) 2017-11-10 2021-11-10 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISORDERS
AU2019264032A1 (en) 2018-05-04 2020-12-03 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US10857163B1 (en) * 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Also Published As

Publication number Publication date
NZ731034A (en) 2024-02-23
MY190408A (en) 2022-04-21
KR20230170816A (ko) 2023-12-19
PH12017500711B1 (en) 2022-12-09
SG11201703073UA (en) 2017-05-30
MX2021008583A (es) 2021-08-11
NZ769008A (en) 2024-03-22
KR102612943B1 (ko) 2023-12-13
MX2017005002A (es) 2018-01-23
US20230113666A1 (en) 2023-04-13
US20170240589A1 (en) 2017-08-24
AU2015331749A1 (en) 2017-05-04
CA2964766A1 (en) 2016-04-21
CN118344423A (zh) 2024-07-16
CO2017004649A2 (es) 2017-11-10
EP4527461A3 (en) 2025-06-25
US20240368213A1 (en) 2024-11-07
BR112017007902B1 (pt) 2023-12-05
WO2016061527A1 (en) 2016-04-21
IL291533B2 (en) 2025-01-01
CN107404877A (zh) 2017-11-28
IL291533A (en) 2022-05-01
RU2017116732A (ru) 2018-11-16
PH12021550427A1 (en) 2022-11-07
RU2017116732A3 (enExample) 2019-02-28
CN117024502A (zh) 2023-11-10
JP2022009567A (ja) 2022-01-14
US11530237B2 (en) 2022-12-20
TW202235090A (zh) 2022-09-16
AU2021218132B2 (en) 2024-05-23
JP7455098B2 (ja) 2024-03-25
TWI762436B (zh) 2022-05-01
MX384728B (es) 2025-03-14
JP2020128420A (ja) 2020-08-27
KR20170065661A (ko) 2017-06-13
EP3885352A1 (en) 2021-09-29
IL251721B (en) 2022-04-01
US20220213137A1 (en) 2022-07-07
JP7692944B2 (ja) 2025-06-16
AR102306A1 (es) 2017-02-15
US20200392177A1 (en) 2020-12-17
AU2024213161A1 (en) 2024-09-12
EP3206494A1 (en) 2017-08-23
AU2020202892B2 (en) 2021-08-26
PH12017500711A1 (en) 2017-10-09
IL251721A0 (en) 2017-06-29
EP3885352B1 (en) 2024-11-27
TW201629082A (zh) 2016-08-16
CN118344424A (zh) 2024-07-16
IL291533B1 (en) 2024-09-01
JP7012119B2 (ja) 2022-02-10
EP3206494A4 (en) 2018-07-04
JP2023071871A (ja) 2023-05-23
JO3724B1 (ar) 2021-01-31
AU2024202959A1 (en) 2024-05-23
AU2020202892A1 (en) 2020-05-21
IL315006A (en) 2024-10-01
RU2020131091A (ru) 2020-11-23
US11542297B2 (en) 2023-01-03
US20220220150A1 (en) 2022-07-14
SG10202009859YA (en) 2020-11-27
TWI869654B (zh) 2025-01-11
US12065463B2 (en) 2024-08-20
PE20170925A1 (es) 2017-07-13
BR112017007902A2 (pt) 2018-11-06
CN112940066A (zh) 2021-06-11
SG10202009861SA (en) 2020-11-27
JP2017531019A (ja) 2017-10-19
MX2021004492A (es) 2022-12-05
US20190177358A1 (en) 2019-06-13
CN117024501A (zh) 2023-11-10
CN112961206A (zh) 2021-06-15
RU2733756C2 (ru) 2020-10-06
AU2021218132A1 (en) 2021-09-09
TW202426002A (zh) 2024-07-01
EP4527461A2 (en) 2025-03-26
US10577390B2 (en) 2020-03-03

Similar Documents

Publication Publication Date Title
JP7012119B2 (ja) Ｃｎｓ障害を処置するための組成物および方法
JP6875996B2 (ja) 神経刺激性ステロイド、組成物、およびその使用
JP2020183434A (ja) Ｃｎｓ障害を処置するための組成物および方法
HK40123820A (en) A compound, compositions thereof and this compound for use in methods of treating cns disorders
HK40053469A (en) A compound, compositions thereof and this compound for use in methods of treating cns disorders
HK40053469B (en) A compound, compositions thereof and this compound for use in methods of treating cns disorders
BR122023013319B1 (pt) Compostos, sal farmaceuticamente aceitável, composição farmacêutica, e usos de um composto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210419

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210702

R150 Certificate of patent or registration of utility model

Ref document number: 6909155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250